论文部分内容阅读
目的观察小剂量瑞替普酶与重组链激酶分别联合替罗非班治疗急性ST段抬高性心肌梗死对患者血小板功能的影响。方法将208例急性ST段抬高性心肌梗死患者随机分为研究组和对照组各104例。研究组采用小剂量瑞替普酶联合替罗非班治疗。对照组采用重组链激酶联合替罗非班治疗。分别检测并比较2组患者治疗前后血小板膜表面P选择素(CD62P)阳性细胞百分比、血浆可溶性CD40配体(s CD40L)水平、血浆血小板源性生长因子(PDGF-BB)水平。结果治疗后2组患者CD62P、s CD40L、PDGF-BB均较治疗前有明显降低(P<0.05),但组间比较差异无统计学意义(P>0.05)。结论小剂量瑞替普酶与重组链激酶分别联合替罗非班治疗急性ST段抬高性心肌梗死均可明显降低血小板活性,抑制血小板激活。
Objective To observe the effects of low dose reteplase and recombinant streptokinase combined with tirofiban in the treatment of patients with acute ST-elevation myocardial infarction on platelet function. Methods 208 patients with acute ST-elevation myocardial infarction were randomly divided into study group and control group of 104 cases. The study group was treated with low dose reteplase combined with tirofiban. Control group using recombinant streptokinase combined with tirofiban treatment. The percentages of P-selectin (CD62P) positive cells, soluble CD40 ligand (sCD40L), and platelet-derived growth factor (PDGF-BB) were detected and compared before and after treatment. Results After treatment, CD62P, CD40L and PDGF-BB in two groups were significantly lower than those before treatment (P <0.05), but there was no significant difference between two groups (P> 0.05). Conclusion Both low-dose reteplase and recombinant streptokinase combined with tirofiban can reduce platelet activity and inhibit platelet activation in acute ST-elevation myocardial infarction.